We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
Read MoreHide Full Article
AngioDynamics, Inc. (ANGO - Free Report) is likely to gain from a series of regulatory clearances and a robust product portfolio.
In the past three months, shares of the company have gained 71.2% compared with the industry’s growth of 9.3%.
With a market capitalization of $711.5 million, the company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices, which are generally utilized in minimally invasive, image-guided procedures. The company has a trailing four-quarter earnings surprise of 99.2%, on average.
Let’s delve deeper into the factors that substantiate AngioDynamics’ Zacks Rank #1 (Strong Buy) at present.
Broad Product Line: The company’s product lines include ablation and fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.
The company continues to enjoy healthy demand for its coveted NanoKnife system to treat tumors. On the R&D front, the company continues to focus on investments in its three key technologies, namely AngioVac, Auryon and NanoKnife while working on ways to improve the profitability of its other products. For fiscal 2021, it anticipates R&D expenses between $35 million and $40 million.
The company is on track to deliver two new AngioVac products in the calendar year of 2021. It continued to witness a strong momentum in its NanoKnife suite with surging disposable sales in the second quarter of fiscal 2021, backed by the strong capital sales in fiscal 2020 as well as the increased visibility of this technology’s uniqueness, demonstrated by the comprehensive DIRECT study. NanoKnife probe sales jumped 30% in the fiscal second quarter, driven by 76% growth in the United States. Solid probe sales are led primarily by the increased installed base, resulting from sturdy NanoKnife capital sales.
In September 2020, the company launched the Auryon Atherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease, which includes Critical Limb Ischemia and In-Stent Restenosis. Laser atherectomy procedures with AURYON laser have continued gaining traction along with other procedures.
FDA Approval for DIRECT Study: Earlier, management announced that the company received a nod from the FDA to initiate a clinical study for treating stage III pancreatic cancer. The approval is for an investigational device exemption (IDE) application for NanoKnife Irreversible Electroporation Direct IRE Cancer Treatment clinical study (DIRECT).
The company’s PATHFINDER and DIRECT studies continue to be its primary focus and the activities in these two studies steadily improved through the fiscal second quarter. By the end of this period, 26 DIRECT study sites secured an Institutional Review Board (IRB) approval. PATHFINDER Auryon Registry study with nine sites initiated enrolling subjects. Currently, the company has completed about 75% of its enrollment target and management expects the entire process to be over by the end of the fiscal third quarter.
Which Way Are Estimates Headed?
For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $283.2 million, suggesting an improvement of 7.2% from the year-ago quarter’s reported figure. For adjusted earnings per share, the same stands at a couple of cents, indicating a decline of 77.8% from the prior-year period’s reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Align
Align Technology has a projected long-term earnings growth rate of 19%.
IDEXX has a projected long-term earnings growth rate of 15.8%.
PerkinElmer has an estimated long-term earnings growth rate of 19.5%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
AngioDynamics, Inc. (ANGO - Free Report) is likely to gain from a series of regulatory clearances and a robust product portfolio.
In the past three months, shares of the company have gained 71.2% compared with the industry’s growth of 9.3%.
With a market capitalization of $711.5 million, the company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices, which are generally utilized in minimally invasive, image-guided procedures. The company has a trailing four-quarter earnings surprise of 99.2%, on average.
Let’s delve deeper into the factors that substantiate AngioDynamics’ Zacks Rank #1 (Strong Buy) at present.
Broad Product Line: The company’s product lines include ablation and fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.
The company continues to enjoy healthy demand for its coveted NanoKnife system to treat tumors. On the R&D front, the company continues to focus on investments in its three key technologies, namely AngioVac, Auryon and NanoKnife while working on ways to improve the profitability of its other products. For fiscal 2021, it anticipates R&D expenses between $35 million and $40 million.
The company is on track to deliver two new AngioVac products in the calendar year of 2021. It continued to witness a strong momentum in its NanoKnife suite with surging disposable sales in the second quarter of fiscal 2021, backed by the strong capital sales in fiscal 2020 as well as the increased visibility of this technology’s uniqueness, demonstrated by the comprehensive DIRECT study. NanoKnife probe sales jumped 30% in the fiscal second quarter, driven by 76% growth in the United States. Solid probe sales are led primarily by the increased installed base, resulting from sturdy NanoKnife capital sales.
In September 2020, the company launched the Auryon Atherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease, which includes Critical Limb Ischemia and In-Stent Restenosis. Laser atherectomy procedures with AURYON laser have continued gaining traction along with other procedures.
FDA Approval for DIRECT Study: Earlier, management announced that the company received a nod from the FDA to initiate a clinical study for treating stage III pancreatic cancer. The approval is for an investigational device exemption (IDE) application for NanoKnife Irreversible Electroporation Direct IRE Cancer Treatment clinical study (DIRECT).
The company’s PATHFINDER and DIRECT studies continue to be its primary focus and the activities in these two studies steadily improved through the fiscal second quarter. By the end of this period, 26 DIRECT study sites secured an Institutional Review Board (IRB) approval. PATHFINDER Auryon Registry study with nine sites initiated enrolling subjects. Currently, the company has completed about 75% of its enrollment target and management expects the entire process to be over by the end of the fiscal third quarter.
Which Way Are Estimates Headed?
For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $283.2 million, suggesting an improvement of 7.2% from the year-ago quarter’s reported figure. For adjusted earnings per share, the same stands at a couple of cents, indicating a decline of 77.8% from the prior-year period’s reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Align
Technology (ALGN - Free Report) , IDEXX Laboratories (IDXX - Free Report) and PerkinElmer , each presently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has a projected long-term earnings growth rate of 19%.
IDEXX has a projected long-term earnings growth rate of 15.8%.
PerkinElmer has an estimated long-term earnings growth rate of 19.5%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>